Download PDF
Semin Respir Crit Care Med 2015; 36(04): 491-507
DOI: 10.1055/s-0035-1555610
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Smoking Cessation in Chronic Obstructive Pulmonary Disease

Donald P. Tashkin
1   Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
03 August 2015 (online)

    Permissions and Reprints

Abstract

Smoking cessation is the most effective strategy for slowing down the progression of chronic obstructive pulmonary disease (COPD) and reducing mortality in the approximately 50% of patients with diagnosed COPD who continue to smoke. While behavioral interventions (including simple advice) have modest efficacy in improving smoking quit rates, the combination of counseling and pharmacotherapy is more effective than either alone. When combined with even brief counseling, nicotine replacement therapy (NRT), bupropion SR, and varenicline have all been shown to be effective in promoting smoking cessation and sustained abstinence in smokers with COPD to a degree comparable to that observed in the general smoking population. However, the recidivism rate is high after initial quitting so that at the end of 1 year, approximately 80% or more of patients are still smoking. Thus, new approaches to smoking cessation are needed. One approach is to combine different pharmacotherapies, for example, nicotine patch plus rapidly acting NRT (e.g., gum or nasal spray) and/or bupropion or even varenicline plus either NRT or bupropion, in a stepwise approach over a varying duration depending on the severity of nicotine dependence and nicotine withdrawal symptoms during the quit attempt, as proposed in the American College of Chest Physicians Tobacco Dependence Took Kit. Electronic (e)-cigarettes, which deliver vaporized nicotine without most of the noxious components in the smoke from burning tobacco cigarettes, also has potential efficacy as a smoking cessation aid, but their efficacy and safety as either substitutes for regular cigarettes or smoking cessation aids require additional study. This task is complicated because e-cigarettes are currently unregulated and hundreds of different brands are currently available.

Keywords

smoking cessation - COPD - behavioral counseling - nicotine replacement therapy - bupropion SR - varenicline - combination pharmacotherapy - electronic cigarettes
 

  • References

  • 1 From the Global Initiative for Chronic Obstructive Lung Disease.. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD). 2014 Update. Available at: http://www.goldcopd.org/
    PubMedGoogle Scholar
  • 2 Schauer GL, Wheaton AG, Malarcher AM, Croft JB. Smoking prevalence and cessation characteristics among U.S. adults with and without COPD: findings from the 2011 Behavioral Risk Factor Surveillance System. COPD 2014; 11 (6) 697-704
    CrossrefPubMedGoogle Scholar
  • 3 Jiménez-Ruiz CA, Masa F, Miravitlles M , et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119 (5) 1365-1370
    CrossrefPubMedGoogle Scholar
  • 4 Hilberink SR, Jacobs JE, Schlösser M, Grol RP, de Vries H. Characteristics of patients with COPD in three motivational stages related to smoking cessation. Patient Educ Couns 2006; 61 (3) 449-457
    CrossrefPubMedGoogle Scholar
  • 5 Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1 (6077) 1645-1648
    CrossrefPubMedGoogle Scholar
  • 6 Anthonisen NR, Connett JE, Kiley JP , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272 (19) 1497-1505
    CrossrefPubMedGoogle Scholar
  • 7 Scanlon PD, Connett JE, Waller LA , et al; Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161 (2, Pt 1) 381-390
    CrossrefPubMedGoogle Scholar
  • 8 Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166 (5) 675-679
    CrossrefPubMedGoogle Scholar
  • 9 Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999; 106 (4) 410-416
    CrossrefPubMedGoogle Scholar
  • 10 Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE ; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142 (4) 233-239
    CrossrefPubMedGoogle Scholar
  • 11 Godtfredsen NS, Lam TH, Hansel TT , et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 2008; 32 (4) 844-853
    CrossrefPubMedGoogle Scholar
  • 12 Calverley PM, Anderson JA, Celli B , et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356 (8) 775-789
    CrossrefPubMedGoogle Scholar
  • 13 Rennard SI, Tashkin DP, McElhattan J , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69 (5) 549-565
    CrossrefPubMedGoogle Scholar
  • 14 Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130 (2) 334-342
    CrossrefPubMedGoogle Scholar
  • 15 Tashkin DP, Rennard S, Hays JT , et al. Lung function and respiratory symptoms in a 1year randomized smoking cessation trial of varenicline in COPD patients. Respir Med 2011; 105: 1682-1690
    CrossrefPubMedGoogle Scholar
  • 16 Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med 2011; 105 (3) 477-484
    CrossrefPubMedGoogle Scholar
  • 17 Foulds J, Gandhi KK, Steinberg MB , et al. Factors associated with quitting smoking at a tobacco dependence treatment clinic. Am J Health Behav 2006; 30 (4) 400-412
    CrossrefPubMedGoogle Scholar
  • 18 Hyland A, Li Q, Bauer JE, Giovino GA, Steger C, Cummings KM. Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res 2004; 6 (Suppl. 03) S363-S369
    CrossrefPubMedGoogle Scholar
  • 19 Bednarek M, Gorecka D, Wielgomas J , et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61 (10) 869-873
    CrossrefPubMedGoogle Scholar
  • 20 Stratelis G, Mölstad S, Jakobsson P, Zetterström O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006; 24 (3) 133-139
    CrossrefPubMedGoogle Scholar
  • 21 Gratziou Ch, Florou A, Ischaki E , et al. Smoking cessation effectiveness in smokers with COPD and asthma under real life conditions. Respir Med 2014; 108 (4) 577-583
    CrossrefPubMedGoogle Scholar
  • 22 Tashkin D, Kanner R, Bailey W , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357 (9268) 1571-1575
    CrossrefPubMedGoogle Scholar
  • 23 Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res 2007; 9 (1) 21-32
    CrossrefPubMedGoogle Scholar
  • 24 Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009; 33 (4) 754-762
    CrossrefPubMedGoogle Scholar
  • 25 Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336 (7644) 598-600
    CrossrefPubMedGoogle Scholar
  • 26 Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; 18 (4) CD000165
    PubMedGoogle Scholar
  • 27 Rice VH, Stead F. Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2004; 1: CD001188 [Update in Cochrane Database Syst Rev 2008;(1):CD001188]
    PubMedGoogle Scholar
  • 28 Morgan MD, Britton JR. Chronic obstructive pulmonary disease 8: non-pharmacological management of COPD. Thorax 2003; 58 (5) 453-457
    CrossrefPubMedGoogle Scholar
  • 29 Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society. Br Med J (Clin Res Ed) 1983; 286 (6365) 595-597
    CrossrefPubMedGoogle Scholar
  • 30 Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; 2 (2) CD001292
    PubMedGoogle Scholar
  • 31 Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2006; 3 (3) CD002850
    PubMedGoogle Scholar
  • 32 Borland R, Segan CJ, Livingston PM, Owen N. The effectiveness of callback counselling for smoking cessation: a randomized trial. Addiction 2001; 96 (6) 881-889
    CrossrefPubMedGoogle Scholar
  • 33 O'Hara P, Grill J, Rigdon MA, Connett JE, Lauger GA, Johnston JJ ; The Lung Health Study Research Group. Design and results of the initial intervention program for the Lung Health Study. Prev Med 1993; 22 (3) 304-315
    CrossrefPubMedGoogle Scholar
  • 34 Willemse B, Lesman-Leegte I, Timens W, Postma D, ten Hacken N. High cessation rates of cigarette smoking in subjects with and without COPD. Chest 2005; 128 (5) 3685-3687
    CrossrefPubMedGoogle Scholar
  • 35 Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am 1992; 76 (2) 415-437
    PubMedGoogle Scholar
  • 36 US Public Health Service Guideline for Tobacco Cessation Treatment; 2008 update. Available at: http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08
    PubMedGoogle Scholar
  • 37 Tashkin DP, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. Respir Med 2009; 103 (7) 963-974
    CrossrefPubMedGoogle Scholar
  • 38 Patel DR, Feucht C, Reid L, Patel ND. Pharmacologic agents for smoking cessation: a clinical review. Clin Pharmacol 2010; 2: 17-29
    PubMedGoogle Scholar
  • 39 Heatherton TF, Kozlowski LT, Frecker RC, Fagerström K-O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86 (9) 1119-1127
    CrossrefPubMedGoogle Scholar
  • 40 Hurt RD, Sachs DP, Glover ED , et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337 (17) 1195-1202
    CrossrefPubMedGoogle Scholar
  • 41 Jorenby DE, Leischow SJ, Nides MA , et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340 (9) 685-691
    CrossrefPubMedGoogle Scholar
  • 42 Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165 (19) 2286-2292
    CrossrefPubMedGoogle Scholar
  • 43 Tapper AR, McKinney SL, Nashmi R , et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004; 306 (5698) 1029-1032
    CrossrefPubMedGoogle Scholar
  • 44 Obach RS, Reed-Hagen AE, Krueger SS , et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006; 34 (1) 121-130
    PubMedGoogle Scholar
  • 45 Gonzales D, Rennard SI, Nides M , et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 47-55
    CrossrefPubMedGoogle Scholar
  • 46 Jorenby DE, Hays JT, Rigotti NA , et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 56-63
    CrossrefPubMedGoogle Scholar
  • 47 Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139 (3) 591-599
    CrossrefPubMedGoogle Scholar
  • 48 Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121 (2) 221-229
    CrossrefPubMedGoogle Scholar
  • 49 Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR ; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 64-71
    CrossrefPubMedGoogle Scholar
  • 50 Di Marco F, Verga M, Reggente M , et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med 2006; 100 (10) 1767-1774
    CrossrefPubMedGoogle Scholar
  • 51 Barr RG, Celli BR, Mannino DM , et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122 (4) 348-355
    CrossrefPubMedGoogle Scholar
  • 52 Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183 (12) 1359-1366
    CrossrefPubMedGoogle Scholar
  • 53 Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856
    CrossrefPubMedGoogle Scholar
  • 54 Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128 (4) 2005-2011
    CrossrefPubMedGoogle Scholar
  • 55 Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003) 2008; 48 (5) 659-665
    CrossrefPubMedGoogle Scholar
  • 56 Kuehn BM. Updated US smoking cessation guideline advises counseling, combining therapies. JAMA 2008; 299 (23) 2736
    CrossrefPubMedGoogle Scholar
  • 57 Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009; 11 (5) 572-576
    CrossrefPubMedGoogle Scholar
  • 58 Tulloch H, Pipe A, Els C , et al. Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial. Contemp Clin Trials 2014; 38 (2) 304-313
    CrossrefPubMedGoogle Scholar
  • 59 Ebbert JO, Hatsukami DK, Croghan IT , et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014; 311 (2) 155-163
    CrossrefPubMedGoogle Scholar
  • 60 Issa JS, Abe TO, Moura S, Santos PC, Pereira AC. Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine Tob Res 2013; 15 (6) 1146-1150
    CrossrefPubMedGoogle Scholar
  • 61 Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 2014; 171 (11) 1199-1205
    CrossrefPubMedGoogle Scholar
  • 62 Paone G, Serpilli M, Girardi E , et al. The combination of a smoking cessation programme with rehabilitation increases stop-smoking rate. J Rehabil Med 2008; 40 (8) 672-677
    CrossrefPubMedGoogle Scholar
  • 63 Nides M, Rand C, Dolce J , et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 1994; 13 (4) 354-361
    CrossrefPubMedGoogle Scholar
  • 64 Luker KA, Chalmers KI, Caress AL, Salmon MP. Smoking cessation interventions in chronic obstructive pulmonary disease and the role of the family: a systematic literature review. J Adv Nurs 2007; 59 (6) 559-568
    CrossrefPubMedGoogle Scholar
  • 65 van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013; 8: CD006102
    PubMedGoogle Scholar
  • 66 Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J 2009; 34 (3) 634-640
    CrossrefPubMedGoogle Scholar
  • 67 Simmons MS, Connett JE, Nides MA , et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J 2005; 25 (6) 1011-1017
    CrossrefPubMedGoogle Scholar
  • 68 Rennard SI, Daughton D, Fujita J , et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 1990; 3 (7) 752-759
    PubMedGoogle Scholar
  • 69 Jiménez-Ruiz C, Solano S, Viteri SA, Ferrero MB, Torrecilla M, Mezquita MH. Harm reduction—a treatment approach for resistant smokers with tobacco-related symptoms. Respiration 2002; 69 (5) 452-455
    CrossrefPubMedGoogle Scholar
  • 70 Tønnesen P. Smoking reduction for smokers not able or motivated to quit?. Respiration 2002; 69 (6) 475-478
    CrossrefPubMedGoogle Scholar
  • 71 Falba T, Jofre-Bonet M, Busch S, Duchovny N, Sindelar J. Reduction of quantity smoked predicts future cessation among older smokers. Addiction 2004; 99 (1) 93-102
    PubMedGoogle Scholar
  • 72 Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res 2006; 8 (6) 739-749
    CrossrefPubMedGoogle Scholar
  • 73 Lindson-Hawley N, Aveyard P, Hughes JR. Gradual reduction vs abrupt cessation as a smoking cessation strategy in smokers who want to quit. JAMA 2013; 310 (1) 91-92
    CrossrefPubMedGoogle Scholar
  • 74 Lindson-Hawley N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012; 11: CD008033
    PubMedGoogle Scholar
  • 75 American College of Chest Physicians.. ACCP Tobacco-Dependence Toolkit, 3rd Edition. More than a guideline…a bridge from what you know to what you do. Available at: http://tobaccodependence.chestnet.org
    PubMedGoogle Scholar
  • 76 Sachs DPL. Tobacco dependence treatment: time to change the paradigm. Chest 2006; 129 (4) 836-839
    CrossrefPubMedGoogle Scholar
  • 77 Hatsukami DK, Jorenby DE, Gonzales D , et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011; 89 (3) 392-399
    CrossrefPubMedGoogle Scholar
  • 78 Bierut LJ, Madden PA, Breslau N , et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 2007; 16 (1) 24-35
    PubMedGoogle Scholar
  • 79 Bierut LJ, Stitzel JA, Wang JC , et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008; 165 (9) 1163-1171
    Google Scholar
  • 80 Kaur-Knudsen D, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. J Clin Oncol 2011; 29 (21) 2875-2882
    CrossrefPubMedGoogle Scholar
  • 81 Kaur-Knudsen D, Nordestgaard BG, Bojesen SE. CHRNA3 genotype, nicotine dependence, lung function and disease in the general population. Eur Respir J 2012; 40 (6) 1538-1544
    CrossrefPubMedGoogle Scholar
  • 82 Budulac SE, Vonk JM, Postma DS, Siedlinski M, Timens W, Boezen MH. Nicotinic acetylcholine receptor variants are related to smoking habits, but not directly to COPD. PLoS ONE 2012; 7 (3) e33386
    CrossrefPubMedGoogle Scholar
  • 83 Quaak M, van Schayck CP, Knaapen AM, van Schooten FJ. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?. Eur Respir J 2009; 33 (3) 468-480
    CrossrefPubMedGoogle Scholar
  • 84 Zhu S-H, Sun JY, Bonnevie E , et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control 2014; 23 (Suppl. 03) iii3-iii9
    Google Scholar
  • 85 Bertholon JF, Becquemin MH, Annesi-Maesano I, Dautzenberg B. Electronic cigarettes: a short review. Respiration 2013; 86 (5) 433-438
    PubMedGoogle Scholar
  • 86 Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control 2010; 19 (2) 98-103
    CrossrefPubMedGoogle Scholar
  • 87 Heavner K, Dunworth J, Bergen P , et al. Electronic cigarettes (e-cigarettes) as potential tobacco harm reduction products. Results of an online survey of e-cigarette users, 2009. Available at: http://tobaccoharmreduction.org/wpapers/011.htm (Accessed March 1, 2011)
    PubMedGoogle Scholar
  • 88 Etter JF. Electronic cigarettes: a survey of users. BMC Public Health 2010; 10: 231
    CrossrefPubMedGoogle Scholar
  • 89 Etter J-F, Bullen C, Flouris AD, Laugesen M, Eissenberg T. Electronic nicotine delivery systems: a research agenda. Tob Control 2011; 20 (3) 243-248
    CrossrefPubMedGoogle Scholar
  • 90 Bullen C, Howe C, Laugesen M , et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382 (9905) 1629-1637
    CrossrefPubMedGoogle Scholar
  • 91 Caponnetto P, Campagna D, Cibella F , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS ONE 2013; 8 (6) e66317
    CrossrefPubMedGoogle Scholar
  • 92 Etter J-F, Bullen C. A longitudinal study of electronic cigarette users. Addict Behav 2014; 39 (2) 491-494
    CrossrefPubMedGoogle Scholar
  • 93 Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 2014; 109 (9) 1531-1540
    CrossrefPubMedGoogle Scholar
  • 94 Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 2014; 5 (2) 67-86
    CrossrefPubMedGoogle Scholar
  • 95 Varughese S, Teschke K, Brauer M, Chow Y, van Netten C, Kennedy SM. Effects of theatrical smokes and fogs on respiratory health in the entertainment industry. Am J Ind Med 2005; 47 (5) 411-418
    CrossrefPubMedGoogle Scholar
  • 96 Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest 2012; 141 (6) 1400-1406
    CrossrefPubMedGoogle Scholar
  • 97 Hureaux J, Drouet M, Urban T. A case report of subacute bronchial toxicity induced by an electronic cigarette. Thorax 2014; 69 (6) 596-597
    CrossrefPubMedGoogle Scholar
  • 98 Polosa R, Campagna D, Tashkin D. Subacute bronchial toxicity induced by an electronic cigarette: take home message. Thorax 2014; 69 (6) 588
    PubMedGoogle Scholar
  • 99 Cummings KM, Giovino G, Jaén CR, Emrich LJ. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav 1985; 10 (4) 373-381
    CrossrefPubMedGoogle Scholar
  • 100 Hua M, Alfi M, Talbot P. Health-related effects reported by electronic cigarette users in online forums. J Med Internet Res 2013; 15 (4) e59
    CrossrefPubMedGoogle Scholar
  • 101 Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: An internet survey. Drug Alcohol Rev 2013; 32 (2) 133-140
    CrossrefPubMedGoogle Scholar
  • 102 Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int J Environ Res Public Health 2014; 11 (4) 4356-4373
    CrossrefPubMedGoogle Scholar
  • 103 ATS/ERS Statement on COPD Research: Existing Evidence, Knowledge Gaps and Recommendations for future research: Smoking cessation. 2014 ATS international conference, San Diego, CA, May 2014
    PubMedGoogle Scholar